

- homa of the uterine corpus. *Leuk Lymphoma* 2006; 47(1): 141–5.
19. Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. *Oncologist* 2006; 11(4): 375–383.
 20. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphoma in adults. *Semin Oncol* 1980; 7: 322–329.
 21. National Comprehensive Cancer Network, Practice guidelines in Oncology, version 3.2007.
 22. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. *Am J Med* 1980; 68: 486–491.
 23. Belada D, Trněný M, et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy II. 3. vyd. Praha, 2007; 33–35.
 24. Yustein JT, Dang V. Biology and treatment of Burkitt's lymphoma. *Curr Opin Hematol* 2007; 14: 375–381.
 25. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. *Blood* 2004; 104(10): 3009–3020.
 26. Magrath IT, Haddy TB, Adde MA. Treatment of patients with high grade non-Hodgkin's lymphomas and central nervous system involvement: is radiation an essential component of therapy? *Leuk Lymphoma* 1996; 21(1–2): 99–105.
 27. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults: a retrospective study of 65 adults treated with the LMB pediatric protocols. *Blood* 1995; 85(3): 664–674.
 28. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. *J Clin Oncol* 1996; 14(3): 925–934.
 29. Todeschini G, Tecchio C, Degani D, et al. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. *Ann Oncol* 1997; 8 (Suppl 1): 77–81.
 30. Longo DL, Duffey PL, Jaffe ES, et al. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. *J Clin Oncol* 1994; 12(10): 2153–2159.
 31. Diviné M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. *Ann Oncol* 2005; 16(12): 1928–1935.
 32. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. *Blood* 1996; 87(2): 495–508.
 33. Hoelzer D, Hiddemann W, Baumann A, et al. High cure rate of adult Burkitt's and other high grade NHL by the combination of short intensive chemotherapy cycles with rituximab. *Haematologica* 2007; 92(S1): 151.
 34. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. *Ann Oncol* 2002; 13(8): 1264–1274.
 35. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. *J Clin Oncol* 1999; 17(8): 2461–2470.
 36. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. *Cancer* 2006; 106(7): 1569–1580.
 37. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. *J Clin Oncol* 2006; 24(25): 4123–4128.
 38. Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. *J Clin Oncol* 1996; 14(9): 2465–2472.
 39. Imhoff GW, Holt B, MacKenzie MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. *Leukemia* 2005; 19(6): 945–952.
 40. Song KW, Barnett MJ, Gascoyne RD, et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. *Br J Haematol* 2006; 133(6): 634–637.
 41. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. *Blood* 2005; 105(3): 948–958.

MUDr. Lenka Šmardová
Interní hematologická klinika
Fakultní nemocnice Brno
Jihlavská 20
602 00 Brno
e-mail: lsmardova@fnbrno.cz

Došlo do redakce: 11. 3. 2008
Přijato: 6. 5. 2008

VZDĚLÁVACÍ AKCE IPVZ

Subkatedra hematologie a transfuzního lékařství

ÚHKT, U Nemocnice 1, 128 08 Praha 2

Vedoucí: doc. MUDr. Jaroslav Čermák, CSc., tel. 224 962 839, fax 224 962 857, e-mail: jaroslav.cermak@uhkt.cz

Subkatedra hematologie a transfuzního lékařství

209282102 Kurz - Novinky v hematologii a transfuzním lékařství – 2. část

*Určeno zejména pro lékaře hematologických, interních a transfuzních oddělení.

Program: Myeloproliferativní choroby, akutní leukemie, poruchy destičkové řady, poruchy metabolismu železa.

Novinky v diagnostice a léčbě jednotlivých chorob, novinky v transfuzním lékařství.

Vedoucí: doc. MUDr. J. Čermák, CSc.

Místo konání: Praha 4, Budějovická 15, Hotel ILF

Předpokládaná cena: 1000 Kč

13. 11. 2008 – 14. 11. 2008